Evidence

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

June 1, 2019

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: R. Wuerstlein, R. Kates, O. Gluz, E.M. Grischke, C. Schem, M. Thill, S. Hasmueller, A. Köhler, B. Otremba, F. Griesinger, C. Schindlbeck, A. Trojan, F. Otto, M. Knauer, R. Pusch, N. Harbeck, WSG-PRIMe investigators in Germany, Austria, Switzerland SUMMARY: MammaPrint and BluePrint test results strongly impacted physicians’ therapy…

Read more

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

November 1, 2017

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Laura J. van ‘t Veer, Christina Yau, Nancy Y. Yu, Christopher C. Benz, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Laura J. Esserman, Linda Sofie Lindström SUMMARY: 20yr BCSS and 10yr DMFS analysis of MammaPrint High Risk vs Low Risk patients in the STO trial. Read more: van’t Veer…

Read more

A Breast Cancer Gene Signature for Indolent Disease

July 1, 2017

PUBLICATION: Breast Cancer Res Treat. 2017 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. AUTHORS: Leonie J.M.J. Delahaye, Caroline A. Drukker, Christa Dreezen, Anke Witteveen, Bob Chan, Mireille Snel, Inès J. Beumer, Rene Bernards, M. William Audeh, Laura J. van’t Veer, Annuska M. Glas SUMMARY: An Ultralow Risk development paper. In an independent validation cohort, we show that patients…

Read more

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

August 27, 2016

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Raquel A. Nunes, Lynette Wray, Mihriye Mete, Pia Herbolsheimer, Karen L. Smith, Lana Bijelic, Marc E. Boisvert, Sandra M. Swain SUMMARY: We evaluated gene expression in tumors from AAF presenting with early stage or locally advanced breast cancer using MammaPrint, BluePrint (molecular subtype) and TargetPrint, correlated with OncotypeDX…

Read more

Equivalence of MammaPrint Array Types in Clinical Trials and Diagnostics

March 22, 2016

PUBLICATION: Breast Cancer Res Treat (2016) 156: 279. https://doi.org/10.1007/s10549-016-3764-5 AUTHORS: Inès Beumer, Anke Witteveen, Leonie Delahaye, Diederik Wehkamp, Mireille Snel, Christa Dreezen, John Zheng, Arno Floore, Guido Brink, Bob Chan, Sabine Linn, Rene Bernards, Laura van ’t Veer, Annuska Glas SUMMARY: Here we demonstrate the equivalence and reproducibility of the MammaPrint test on both customized certified array types,…

Read more

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

November 1, 2015

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Katharine Yao, Robert Goldschmidt, Mary TurkJelle Wesseling, Lisette Stork-Sloots, Femke de Snoo, Massimo Cristofanilli SUMMARY: Retrospective, observational study comparing MP+BP subtyping with long-term outcomes: MammaPrint low-risk patients had a 10-year DMFS of 96 % (95 %CI 92.8–99.4), while MammaPrint high-risk patients had a 10-year DMFS of 87%. Read…

Read more

Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

November 24, 2014

PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: C.A. Drukker, S.G. Elias, M.V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P.W. Whitworth, R.R. Patel, F.A. de Snoo, L.J. van ’t Veer, P.D. Beitsch, E.J. Th. Rutgers SUMMARY: After a median follow-up of 8.96 years with 87 LRRs, patients with a high-risk 70-gene signature (n…

Read more

Optimized Outcome Prediction in Breast Cancer by Combining the 70-Gene Signature with Clinical Risk Prediction Algorithms

June 1, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24. AUTHORS: C.A. Drukker, M.V. Nijenhuis, J.M. Bueno-de-Mesquita, V.P. Retèl, W.H. van Harten, H. van Tinteren, J. Wesseling, M.K. Schmidt, L.J. van’t Veer, G.S. Sonke, E.J. T. Rutgers, M.J. van de Vijver, S.C. Linn SUMMARY: In this cohort, the PREDICT plus tool in combination with the…

Read more

Mammographic Screening Detects Low-Risk Tumor Biology Breast Cancers

February 2, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;144(1):103-11. doi: 10.1007/s10549-013-2830-5. Epub 2014 Jan 28.7 AUTHORS: Drukker C.A., Schmidt M.K., Rutgers E.J., Cardoso F., Kerlikowske K., Esserman L.J., van Leeuwen F.E., Pijnappel R.M., Slaets L., Bogaerts J., Van’t Veer L.J. SUMMARY: Among the screen-detected cancers, 32 % had a 70-gene signature high-risk and 68 % a low-risk tumor, of which…

Read more

Long-Term Impact of the 70-Gene Signature on Breast Cancer Outcome

February 1, 2014

PUBLICATION: Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21. AUTHORS: Drukker C.A., van Tinteren H., Schmidt M.K., Rutgers E.J., Bernards R., van de Vijver M.J., Van’t Veer L.J. SUMMARY: MammaPrint showed a significant absolute difference in DMFS and OS at 25 years between the patients with a low-risk 70-gene signature (60.4 and 57.3 %…

Read more

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

June 12, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Glück S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in patients with early-stage breast cancer using BluePrint and…

Read more

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

June 1, 2013

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chéreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence that their routine use was cost saving or…

Read more

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

November 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub 2012 Sep 8. AUTHORS: Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., Loo C.E., Vrancken-Peeters M.J., Sonke G.S., Berry D.A., Van’t Veer L.J., Esserman L.J., Wesseling J., Rodenhuis S., Shelley Hwang E.; I-SPY TRIAL Investigators. SUMMARY: Expression subtyping, particularly the NKI 70-gene signature,…

Read more

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrint®) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

June 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Kondo M., Hoshi S.L., Ishiguro H., Toi M. SUMMARY: The introduction of the assay into Japanese practice of ER+, LN−, HER2− ESBC treatment by including it to Japan’s social health insurance benefit package has a reasonable chance to be judged as cost-effective and may be justified as an…

Read more

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

May 1, 2012

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Oscar Krijgsman, Paul Roepman, Wilbert Zwart, Jason S. Carroll, Sun Tian, Femke A. de Snoo, Richard A. Bender, Rene Bernards, Annuska M. Glas SUMMARY: BluePrint classification of a patient cohort that was treated with neoadjuvant chemotherapy (n = 133) shows improved distribution of pathological Complete Response (pCR), among…

Read more

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

January 1, 2012

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retèl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Treat_Retel et al_The 21-gene has the highest probability…

Read more

The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study

July 27, 2009

PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27. AUTHORS: Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., Glas A.M., Bogaerts J., Cardoso F., Piccart-Gebhart M.J., Rutgers E.T., Van’t Veer L.J.; TRANSBIG Consortium. SUMMARY: Among 1-3 LN+ patients, the 10-year distant metastasis-free (DMFS) and breast cancer specific survival (BCSS) probabilities…

Read more